Prostate cancer: 2. Natural history

Nam, Robert K.; Jewett, Michael A.S.; Krahn, Murray D.
September 1998
CMAJ: Canadian Medical Association Journal;09/22/98, Vol. 159 Issue 6, p685
Academic Journal
Presents the second in a 13-part series about the treatment of prostate cancer. Natural history of adenocarcinoma of the prostate; Effect of age and comorbidity on prognosis; Watchful waiting versus definitive treatment; Methods for assessing prognosis; Results of prognostic studies.


Related Articles

  • Prostate cancer: 6. Surgical treatment of localized disease. Goldenberg, S. Larry; Ramsey, Ernest W.; Jewett, Michael A.S. // CMAJ: Canadian Medical Association Journal;11/17/98, Vol. 159 Issue 10, p1265 

    Describes the case of a 65-year-old man diagnosed with prostate adenocarcinoma. Excellent general health; Question of whether to have surgery or radiation treatment; Candidates for radical prostatectomy; Procedures; Informing the patient; Details about surgery; Expectations after surgery; Early...

  • Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Narita, Shintaro; Tsuchiya, Norihiko; Yuasa, Takeshi; Maita, Shinya; Obara, Takashi; Numakura, Kazuyuki; Tsuruta, Hiroshi; Saito, Mitsuru; Inoue, Takamitsu; Horikawa, Yohei; Satoh, Shigeru; Habuchi, Tomonori // International Journal of Clinical Oncology;Jun2012, Vol. 17 Issue 3, p204 

    Objectives: Docetaxel-based chemotherapy is effective in patients with castration-resistant prostate cancer (CRPC). This phase II study assessed the outcome and predictive factors for prognosis and toxicity following intermittent chemotherapy with docetaxel, estramustine phosphate, and...

  • Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators. Makarewicz, Roman; Zyromska, Agnieszka; Andrusewicz, Hanna // Folia Histochemica et Cytobiologica;2011, Vol. 49 Issue 3, p452 

    The prognosis in prostate cancer depends on several clinical-morphological factors, such as Gleason score, pTNM and preoperative PSA level. Reliable biological markers are being sought to supplement clinicalmorphological data in order to better predict prognosis and to select an individualized...

  • Evaluation of prediction models for the staging of prostate cancer. Boyce, Susie; Fan, Yue; Watson, Ronald William; Murphy, Thomas Brendan // BMC Medical Informatics & Decision Making;2013, Vol. 13 Issue 1, p1 

    Background There are dilemmas associated with the diagnosis and prognosis of prostate cancer which has lead to over diagnosis and over treatment. Prediction tools have been developed to assist the treatment of the disease. Methods A retrospective review was performed of the Irish Prostate Cancer...

  • BEST OF THE BLOGS.  // HealthLeaders Magazine;Jul2009, Vol. 12 Issue 7, p11 

    The article presents blog highlights from HealthLeaders Media for the month of July 2009 including one blog about the treatment of prostate cancer, a blog by physician Steven Tucker about the prognosis for men with prostate cancer and another one on the use of Twitter to describe surgeries in...

  • Decreased expression of stromal estrogen receptor α and β in prostate cancer. Daniels, Garrett; Gellert, Lan Lin; Melamed, Jonathan; Hatcher, David; Yirong Li; Jianjun Wei; Jinhua Wang; Peng Lee // American Journal of Translational Research;2014, Vol. 6 Issue 2, p140 

    Background: Recently there has been an increased interest in the role of tumor-associated stroma in prostate tumorigenesis, but little is known about the respective roles of stomal ERα and ERβ in prostate cancer (PCa). This study characterizes the expression patterns of ERα and ERβ...

  • Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers. Laderach, Diego J.; Gentilini, Lucas; Jaworski, Felipe M.; Compagno, Daniel // Prostate Cancer (20903111);2013, p1 

    A better understanding of multimolecular interactions involved in tumor dissemination is required to identify new effective therapies for advanced prostate cancer (PCa). Several groups investigated protein-glycan interactions as critical factors for crosstalk between prostate tumors and their...

  • Risk stratification of prostate cancer patients based on EPS-urine zinc content. Medarova, Zdravka; Ghosh, Subrata K.; Vangel, Mark; Drake, Richard; Moore, Anna // American Journal of Cancer Research;2014, Vol. 4 Issue 4, p385 

    The early detection of prostate cancer is a life-saving event in patients harboring potentially aggressive disease. With the development of malignancy there is a dramatic reduction in the zinc content of prostate tissue associated with the inability of cancer cells to accumulate the ion. In the...

  • The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. Alkner, S.; Bendahl, PO.; Grabau, D.; Malmström, P.; Fernö, M.; Rydén, L. // Annals of Oncology;May2013, Vol. 24 Issue 5, p1244 

    Background The steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2). Patients and methods Using immunohistochemistry...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics